Intelectin-2 Strengthens Mucosal Defense and Shows Activity Against Resistant Bacteria

In a new study in Nature Communications, intelectin-2 is described as a gut lectin that recognizes the sugar galactose on mucins and on certain bacterial surface carbohydrates.

This carbohydrate-binding behavior serves two related functions at the mucosal surface. When intelectin-2 binds galactose-containing mucins, it can link mucin molecules together, while binding to sugars on bacterial membranes allows the protein to attach directly to microbes. In this way, intelectin-2 both reinforces the mucus barrier and helps trap bacteria that come into contact with it.

The study reports that intelectin-2 from both human and mouse sources binds galactose residues commonly found in mucins, with this interaction leading to cross-linking that strengthens the structural integrity of mucus. At the same time, galactose present on the surface carbohydrates of some bacteria enables intelectin-2 to attach to microbial cells and retain them within the mucus layer. Microbes captured in this environment showed slowed growth and, over time, structural breakdown suggesting a microbicidal effect.

The research describes activity against multiple bacterial species, including examples resistant to conventional antibiotics. Among the organisms highlighted are Staphylococcus aureus and Klebsiella pneumoniae. These findings are presented in the context of experimental observations, indicating antimicrobial effects against several bacterial targets rather than a single species.

The article also reports an association between intelectin-2 levels and inflammatory bowel disease (IBD). Individuals with IBD may show either unusually low or unusually high levels of the protein. The researchers suggest that future therapies aimed at restoring balanced intelectin-2 levels could potentially help manage aspects of the disease, though such approaches remain speculative and have not been established as clinical treatments.

Key Takeaways

• Intelectin-2 binds galactose-containing glycans on mucins and certain bacterial surfaces, enabling both mucus cross-linking and microbial attachment.
• Experimental findings show antimicrobial activity against multiple bacterial species, including antibiotic-resistant examples such as Staphylococcus aureus and Klebsiella pneumoniae.
• Levels of intelectin-2 may be altered in inflammatory bowel disease, suggesting that restoring balanced levels could represent a potential future therapeutic strategy.